falseQ32025--12-3100009106380.02783640.4456328xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesddd:segmentxbrli:pureddd:entityddd:installmentddd:milestoneddd:employeeddd:dayddd:defendant00009106382025-01-012025-09-3000009106382025-10-2900009106382025-09-3000009106382024-12-310000910638us-gaap:ProductMember2025-07-012025-09-300000910638us-gaap:ProductMember2024-07-012024-09-300000910638us-gaap:ProductMember2025-01-012025-09-300000910638us-gaap:ProductMember2024-01-012024-09-300000910638us-gaap:ServiceMember2025-07-012025-09-300000910638us-gaap:ServiceMember2024-07-012024-09-300000910638us-gaap:ServiceMember2025-01-012025-09-300000910638us-gaap:ServiceMember2024-01-012024-09-3000009106382025-07-012025-09-3000009106382024-07-012024-09-3000009106382024-01-012024-09-3000009106382023-12-3100009106382024-09-300000910638us-gaap:CommonStockMember2024-12-310000910638us-gaap:AdditionalPaidInCapitalMember2024-12-310000910638us-gaap:RetainedEarningsMember2024-12-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000910638us-gaap:CommonStockMember2025-01-012025-03-3100009106382025-01-012025-03-310000910638us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000910638us-gaap:RetainedEarningsMember2025-01-012025-03-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000910638us-gaap:CommonStockMember2025-03-310000910638us-gaap:AdditionalPaidInCapitalMember2025-03-310000910638us-gaap:RetainedEarningsMember2025-03-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100009106382025-03-310000910638us-gaap:CommonStockMember2025-04-012025-06-3000009106382025-04-012025-06-300000910638us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000910638us-gaap:RetainedEarningsMember2025-04-012025-06-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300000910638us-gaap:CommonStockMember2025-06-300000910638us-gaap:AdditionalPaidInCapitalMember2025-06-300000910638us-gaap:RetainedEarningsMember2025-06-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-3000009106382025-06-300000910638us-gaap:CommonStockMember2025-07-012025-09-300000910638us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000910638us-gaap:RetainedEarningsMember2025-07-012025-09-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300000910638us-gaap:CommonStockMember2025-09-300000910638us-gaap:AdditionalPaidInCapitalMember2025-09-300000910638us-gaap:RetainedEarningsMember2025-09-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300000910638us-gaap:CommonStockMember2023-12-310000910638us-gaap:AdditionalPaidInCapitalMember2023-12-310000910638us-gaap:RetainedEarningsMember2023-12-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000910638us-gaap:CommonStockMember2024-01-012024-03-310000910638us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100009106382024-01-012024-03-310000910638us-gaap:RetainedEarningsMember2024-01-012024-03-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000910638us-gaap:CommonStockMember2024-03-310000910638us-gaap:AdditionalPaidInCapitalMember2024-03-310000910638us-gaap:RetainedEarningsMember2024-03-310000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100009106382024-03-310000910638us-gaap:CommonStockMember2024-04-012024-06-300000910638us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000009106382024-04-012024-06-300000910638us-gaap:RetainedEarningsMember2024-04-012024-06-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000910638us-gaap:CommonStockMember2024-06-300000910638us-gaap:AdditionalPaidInCapitalMember2024-06-300000910638us-gaap:RetainedEarningsMember2024-06-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000009106382024-06-300000910638us-gaap:CommonStockMember2024-07-012024-09-300000910638us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000910638us-gaap:RetainedEarningsMember2024-07-012024-09-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000910638us-gaap:CommonStockMember2024-09-300000910638us-gaap:AdditionalPaidInCapitalMember2024-09-300000910638us-gaap:RetainedEarningsMember2024-09-300000910638us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000910638us-gaap:CustomerRelationshipsMember2024-01-012024-09-300000910638us-gaap:CustomerRelationshipsMember2024-07-012024-09-300000910638us-gaap:TechnologyBasedIntangibleAssetsMember2024-01-012024-09-300000910638us-gaap:TechnologyBasedIntangibleAssetsMember2024-07-012024-09-300000910638us-gaap:TradeNamesMember2024-01-012024-09-300000910638us-gaap:TradeNamesMember2024-07-012024-09-300000910638us-gaap:PropertyPlantAndEquipmentMember2024-07-012024-09-300000910638us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-09-300000910638us-gaap:CollaborativeArrangementMember2025-07-012025-09-300000910638us-gaap:CollaborativeArrangementMember2025-01-012025-09-300000910638us-gaap:CollaborativeArrangementMember2024-07-012024-09-300000910638us-gaap:CollaborativeArrangementMember2024-01-012024-09-3000009106382025-10-012025-09-300000910638srt:AmericasMember2025-07-012025-09-300000910638srt:AmericasMember2024-07-012024-09-300000910638srt:AmericasMember2025-01-012025-09-300000910638srt:AmericasMember2024-01-012024-09-300000910638us-gaap:EMEAMember2025-07-012025-09-300000910638us-gaap:EMEAMember2024-07-012024-09-300000910638us-gaap:EMEAMember2025-01-012025-09-300000910638us-gaap:EMEAMember2024-01-012024-09-300000910638srt:AsiaPacificMember2025-07-012025-09-300000910638srt:AsiaPacificMember2024-07-012024-09-300000910638srt:AsiaPacificMember2025-01-012025-09-300000910638srt:AsiaPacificMember2024-01-012024-09-300000910638country:US2025-07-012025-09-300000910638country:US2024-07-012024-09-300000910638country:US2025-01-012025-09-300000910638country:US2024-01-012024-09-300000910638country:DE2025-07-012025-09-300000910638country:DE2024-07-012024-09-300000910638country:DE2025-01-012025-09-300000910638country:DE2024-01-012024-09-300000910638ddd:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-07-012025-09-300000910638ddd:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-09-300000910638ddd:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300000910638ddd:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300000910638us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberddd:A3DXpertAndOqtonMember2025-09-300000910638us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberddd:A3DXpertAndOqtonMember2025-09-012025-09-300000910638us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberddd:A3DXpertAndOqtonMember2025-01-012025-09-300000910638us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberddd:GeomagicSoftwareMember2025-04-010000910638us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberddd:GeomagicSoftwareMember2025-01-012025-09-300000910638us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberddd:GeomagicSoftwareMember2024-12-310000910638ddd:EnhatchMember2025-04-012025-06-300000910638ddd:EnhatchMember2025-09-300000910638ddd:GenesisTissueInc.Member2025-09-300000910638ddd:SaudiArabianIndustrialInvestmentsCompanyMember2024-12-012024-12-310000910638ddd:SaudiArabianIndustrialInvestmentsCompanyMember2025-09-300000910638ddd:SaudiArabianIndustrialInvestmentsCompanyMember2024-12-310000910638ddd:HullLegacyMediaCorporationMember2025-02-012025-02-280000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2025-06-230000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2025-06-230000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2025-06-232025-06-230000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2025-06-170000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2021-11-160000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2021-11-162021-11-160000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2025-09-300000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2025-09-300000910638us-gaap:ConvertibleDebtMember2025-09-300000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-12-310000910638us-gaap:ConvertibleDebtMember2024-12-310000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2025-06-012025-06-300000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-03-310000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-03-012024-03-310000910638ddd:ConvertibleSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-01-012024-09-300000910638us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300000910638us-gaap:RestrictedStockMember2025-01-012025-09-300000910638ddd:IncentiveAwardsMember2024-07-012024-09-300000910638ddd:IncentiveAwardsMember2024-01-012024-09-300000910638us-gaap:PhantomShareUnitsPSUsMember2025-09-300000910638us-gaap:PhantomShareUnitsPSUsMember2025-01-012025-09-300000910638ddd:DpPolarGmbHMember2022-10-040000910638ddd:DpPolarGmbHMember2022-10-042022-10-040000910638ddd:DpPolarGmbHMember2025-04-012025-06-300000910638ddd:DpPolarGmbHMember2025-07-012025-09-300000910638ddd:DpPolarGmbHMember2025-01-012025-09-300000910638ddd:DpPolarGmbHMember2024-07-012024-09-300000910638ddd:DpPolarGmbHMember2024-01-012024-09-300000910638ddd:IncentiveAwardsMember2025-07-012025-09-300000910638ddd:IncentiveAwardsMember2025-01-012025-09-3000009106382025-06-2300009106382025-06-232025-06-230000910638us-gaap:AccumulatedTranslationAdjustmentMember2025-06-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-06-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2025-07-012025-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-07-012025-09-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2025-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-09-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000910638us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-300000910638us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000910638us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000910638us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000910638us-gaap:OperatingSegmentsMemberddd:HealthcareSolutionsMember2025-07-012025-09-300000910638us-gaap:OperatingSegmentsMemberddd:HealthcareSolutionsMember2024-07-012024-09-300000910638us-gaap:OperatingSegmentsMemberddd:HealthcareSolutionsMember2025-01-012025-09-300000910638us-gaap:OperatingSegmentsMemberddd:HealthcareSolutionsMember2024-01-012024-09-300000910638us-gaap:OperatingSegmentsMemberddd:IndustrialSolutionsMember2025-07-012025-09-300000910638us-gaap:OperatingSegmentsMemberddd:IndustrialSolutionsMember2024-07-012024-09-300000910638us-gaap:OperatingSegmentsMemberddd:IndustrialSolutionsMember2025-01-012025-09-300000910638us-gaap:OperatingSegmentsMemberddd:IndustrialSolutionsMember2024-01-012024-09-300000910638us-gaap:OperatingSegmentsMember2025-07-012025-09-300000910638us-gaap:OperatingSegmentsMember2024-07-012024-09-300000910638us-gaap:OperatingSegmentsMember2025-01-012025-09-300000910638us-gaap:OperatingSegmentsMember2024-01-012024-09-300000910638us-gaap:MaterialReconcilingItemsMember2025-07-012025-09-300000910638us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300000910638us-gaap:MaterialReconcilingItemsMember2025-01-012025-09-300000910638us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300000910638ddd:HealthcareSolutionsMember2025-07-012025-09-300000910638ddd:HealthcareSolutionsMember2024-07-012024-09-300000910638ddd:HealthcareSolutionsMember2025-01-012025-09-300000910638ddd:HealthcareSolutionsMember2024-01-012024-09-300000910638ddd:IndustrialSolutionsMember2025-07-012025-09-300000910638ddd:IndustrialSolutionsMember2024-07-012024-09-300000910638ddd:IndustrialSolutionsMember2025-01-012025-09-300000910638ddd:IndustrialSolutionsMember2024-01-012024-09-300000910638ddd:ExportControlsAndGovernmentContractsComplianceMember2023-02-012023-02-280000910638ddd:ExportControlsAndGovernmentContractsComplianceMemberddd:DirectorateOfDefenseTradeControlsMember2023-02-012023-02-280000910638ddd:ExportControlsAndGovernmentContractsComplianceMemberddd:BureauOfIndustryAndSecurityOfTheDepartmentOfCommerceMember2023-02-012023-02-280000910638ddd:ExportControlsAndGovernmentContractsComplianceMemberddd:USDepartmentOfJusticeMember2023-02-012023-02-280000910638ddd:ExportControlsAndGovernmentContractsComplianceMember2025-01-012025-03-310000910638ddd:ExportControlsAndGovernmentContractsComplianceMemberddd:DirectorateOfDefenseTradeControlsMember2025-01-012025-03-310000910638ddd:ExportControlsAndGovernmentContractsComplianceMemberddd:DirectorateOfDefenseTradeControlsMember2025-01-012025-09-300000910638us-gaap:FinancialStandbyLetterOfCreditMember2023-06-020000910638us-gaap:FinancialStandbyLetterOfCreditMember2023-06-022023-06-020000910638us-gaap:FinancialStandbyLetterOfCreditMember2025-09-300000910638ddd:VolumetricBiotechnologiesIncMember2021-12-010000910638ddd:VolumetricBiotechnologiesIncMember2021-12-012021-12-010000910638ddd:VolumetricBiotechnologiesIncMember2024-02-242024-02-240000910638ddd:VolumetricBiotechnologiesIncMember2024-02-240000910638ddd:VolumetricBiotechnologiesIncMember2024-03-290000910638ddd:VolumetricBiotechnologiesIncMember2024-03-292024-03-290000910638ddd:VolumetricBiotechnologiesIncMember2024-04-292024-04-290000910638ddd:VolumetricBiotechnologiesIncMember2024-04-290000910638ddd:VolumetricBiotechnologiesIncMember2024-08-212024-08-210000910638ddd:VolumetricBiotechnologiesIncMember2025-01-102025-01-100000910638ddd:IntrepidAutomationMember2021-05-192021-05-190000910638ddd:IntrepidAutomationMember2023-05-012023-05-310000910638ddd:SecuritiesClassActionMember2025-05-122025-05-120000910638us-gaap:MoneyMarketFundsMember2025-09-300000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-09-300000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-09-300000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-09-300000910638us-gaap:MoneyMarketFundsMember2024-12-310000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-12-310000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-12-310000910638us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-12-310000910638ddd:ConvertibleSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2024-12-310000910638srt:MinimumMember2025-09-300000910638srt:MaximumMember2025-09-300000910638us-gaap:EmployeeSeveranceMemberddd:RestructuringPlan2025Member2025-07-012025-09-300000910638us-gaap:EmployeeSeveranceMemberddd:RestructuringPlan2023Member2024-07-012024-09-300000910638us-gaap:EmployeeSeveranceMemberddd:RestructuringPlan2025Member2025-01-012025-09-300000910638us-gaap:EmployeeSeveranceMemberddd:RestructuringPlan2023Member2024-01-012024-09-300000910638ddd:FacilityExitAndOtherRelatedMemberddd:RestructuringPlan2025Member2025-07-012025-09-300000910638ddd:FacilityExitAndOtherRelatedMemberddd:RestructuringPlan2023Member2024-07-012024-09-300000910638ddd:FacilityExitAndOtherRelatedMemberddd:RestructuringPlan2025Member2025-01-012025-09-300000910638ddd:FacilityExitAndOtherRelatedMemberddd:RestructuringPlan2023Member2024-01-012024-09-300000910638ddd:RestructuringPlan2025Member2025-07-012025-09-300000910638ddd:RestructuringPlan2023Member2024-07-012024-09-300000910638ddd:RestructuringPlan2025Member2025-01-012025-09-300000910638ddd:RestructuringPlan2023Member2024-01-012024-09-300000910638us-gaap:CostOfSalesMember2025-07-012025-09-300000910638us-gaap:CostOfSalesMember2024-07-012024-09-300000910638us-gaap:CostOfSalesMember2025-01-012025-09-300000910638us-gaap:CostOfSalesMember2024-01-012024-09-300000910638us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-07-012025-09-300000910638us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000910638us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-09-300000910638us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000910638us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012025-09-300000910638us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000910638us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-09-300000910638us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000910638us-gaap:EmployeeSeveranceMember2024-12-310000910638us-gaap:EmployeeSeveranceMember2025-01-012025-09-300000910638us-gaap:EmployeeSeveranceMember2025-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to____________

Commission File No. 001-34220

__________________________

3D SYSTEMS CORPORATION

(Exact name of Registrant as Specified in its Charter)

__________________________


Delaware			95-4431352
(State or Other Jurisdiction of Incorporation or Organization)			(I.R.S. Employer Identification No.)

333 Three D Systems Circle

Rock Hill, South Carolina 29730

(Address of Principal Executive Offices and Zip Code)

(Registrant’s Telephone Number, Including Area Code): (803) 326-3900

_________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

DDD

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Shares of Common Stock, par value $0.001 per share, outstanding as of October 29, 2025: 128,738,014.

3D SYSTEMS CORPORATION

Table of Contents


			PAGE NUMBER
Part I - Financial Information			3
Item 1. Financial Statements (Unaudited)			3
Condensed Consolidated Balance Sheets			3
Condensed Consolidated Statements of Operations			4
Condensed Consolidated Statements of Comprehensive Income (Loss)			5
Condensed Consolidated Statements of Cash Flows			6
Condensed Consolidated Statements of Stockholders' Equity			8
Notes to the Condensed Consolidated Financial Statements			10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			26
Item 3. Quantitative and Qualitative Disclosures About Market Risk			37
Item 4. Controls and Procedures			37
Part II - Other Information			38
Item 1. Legal Proceedings			38
Item 1A. Risk Factors			38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			38
Item 3. Defaults Upon Senior Securities			38
Item 4. Mine Safety Disclosures			38
Item 5. Other Information			38
Item 6. Exhibits			39
Signatures			40

Table of Content

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

3D SYSTEMS CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)


(in thousands, except par value)	September 30, 2025		December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	95,542	$	171,324
Accounts receivable, net of reserves — $3,072 and $2,433	88,074		101,471
Inventories	132,469		118,530
Prepaid expenses and other current assets	43,582		34,329

Assets held for sale	1,561		3,176
Total current assets	361,228		428,830
Property and equipment, net	52,168		51,044
Intangible assets, net	16,673		18,020
Goodwill	15,573		14,879
Operating lease right-of-use assets	47,798		50,715
Finance lease right-of-use assets	8,119		8,726
Long-term deferred income tax assets	3,217		2,063
Other assets	49,773		34,569
Total assets	$	554,549	$	608,846
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY
Current liabilities:
Current operating lease liabilities	$	11,789	$	9,514
Accounts payable	39,182		41,833
Accrued and other liabilities	48,521		45,488
Customer deposits	2,241		4,712
Deferred revenue	25,540		27,298

Liabilities held for sale	5,077		10,251
Total current liabilities	132,350		139,096
Long-term debt, net of deferred financing costs	122,600		211,995
Long-term operating lease liabilities	47,428		52,527
Long-term deferred income tax liabilities	3,280		2,076
Other liabilities	25,599		25,001
Total liabilities	331,257		430,695
Commitments and contingencies (Note 12)
Redeemable non-controlling interest	2,192		1,958
Stockholders’ equity:
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 128,245 and 135,510 as of September 30, 2025 and December 31, 2024, respectively	128		136
Additional paid-in capital	1,579,809		1,593,366
Accumulated deficit	(1,312,846)		(1,362,243)
Accumulated other comprehensive loss	(45,991)		(55,066)
Total stockholders’ equity	221,100		176,193
Total liabilities, redeemable non-controlling interest and stockholders’ equity	$	554,549	$	608,846

See accompanying notes to condensed consolidated financial statements.

Table of Content

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited)


	Three Months Ended				Nine Months Ended
(in thousands, except per share amounts)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Revenue:
Products	$	52,311	$	72,968	$	160,835	$	208,752
Services	38,938		39,972		119,792		120,345
Total revenue	91,249		112,940		280,627		329,097
Cost of sales:
Products	36,109		47,533		105,748		129,571
Services	25,709		23,694		76,609		69,793
Total cost of sales	61,818		71,227		182,357		199,364
Gross profit	29,431		41,713		98,270		129,733
Operating expenses:
Selling, general and administrative	34,716		57,974		118,624		166,772
Research and development	16,025		20,764		53,069		66,260
Asset impairment charges	—		143,733		—		143,733
Total operating expenses	50,741		222,471		171,693		376,765
Loss from operations	(21,310)		(180,758)		(73,423)		(247,032)
Non-operating income (loss):
Foreign exchange gain (loss), net	2,623		(1,960)		2,171		(774)
Interest income	784		1,550		3,454		5,800
Interest expense	(1,924)		(606)		(3,202)		(1,944)
Gain on disposition	—		—		125,681		—
Other income (loss), net	475		(51)		7,335		21,719
Total non-operating income (loss)	1,958		(1,067)		135,439		24,801
Net (loss) income before income taxes	(19,352)		(181,825)		62,016		(222,231)
Benefit (provision) for income taxes	2,630		4,343		(9,059)		2,496
Loss on equity method investments, net of income taxes	(1,331)		(1,254)		(3,560)		(2,403)
Net (loss) income before redeemable non-controlling interest	(18,053)		(178,736)		49,397		(222,138)
Less: net loss attributable to redeemable non-controlling interest	—		(109)		—		(252)
Net (loss) income attributable to 3D Systems Corporation	$	(18,053)	$	(178,627)	$	49,397	$	(221,886)

Net (loss) income per common share:
Basic	$	(0.14)	$	(1.35)	$	0.38	$	(1.69)
Diluted	$	(0.14)	$	(1.35)	$	0.29	$	(1.69)

Weighted average shares outstanding:
Basic	125,273		132,235		129,979		131,621
Diluted	125,273		132,235		178,397		131,621

See accompanying notes to condensed consolidated financial statements.

Table of Content

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)


	Three Month Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Net (loss) income before redeemable non-controlling interest	$	(18,053)	$	(178,736)	$	49,397	$	(222,138)
Other comprehensive income (loss), net of taxes:
Pension plan adjustments	—		13		20		4

Foreign currency translation	(3,066)		10,150		9,055		1,768



Total other comprehensive (loss) income, net of taxes:	(3,066)		10,163		9,075		1,772
Total comprehensive (loss) income, net of taxes	(21,119)		(168,573)		58,472		(220,366)
Less: comprehensive loss attributable to redeemable non-controlling interest	—		(109)		—		(252)
Comprehensive (loss) income attributable to 3D Systems Corporation	$	(21,119)	$	(168,464)	$	58,472	$	(220,114)

See accompanying notes to condensed consolidated financial statements.

Table of Content

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024
OPERATING ACTIVITIES
Net income (loss) before redeemable non-controlling interest	$	49,397	$	(222,138)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	16,280		27,774
Accretion of debt discount	993		1,063
Stock-based compensation	1,805		17,339


Non-cash operating lease expense	7,382		7,370
Provision for inventory obsolescence	5,158		10,332

Provision for bad debts	1,458		148
(Gain) loss on the disposition of businesses, property, equipment and other assets	(126,251)		1,649

Gain on debt extinguishment	(8,203)		(21,518)
Provision (benefit) for deferred income taxes and reserve adjustments	(1,154)		451
Loss on equity method investment, net of taxes	3,560		2,403
Asset impairment charges	—		143,733
Changes in operating accounts:
Accounts receivable	18,288		2,594
Inventories	(15,474)		5,972
Prepaid expenses and other current assets	(6,422)		6,831
Accounts payable	(4,844)		(7,201)
Deferred revenue and customer deposits	(809)		4,533
Accrued and other liabilities	(2,645)		(9,843)
All other operating activities	(11,650)		(8,601)
Net cash used in operating activities	(73,131)		(37,109)
INVESTING ACTIVITIES
Purchases of property and equipment	(7,995)		(10,798)


Proceeds from sale of assets and businesses, net of cash sold	119,400		96
Acquisitions and other investments, net of cash acquired	(3,400)		(2,450)
Other investing activities	271		—
Net cash provided by (used in) investing activities	108,276		(13,152)
FINANCING ACTIVITIES


Proceeds from borrowings	92,030		—
Debt issuance costs	(3,425)		—
Repayment of borrowings and long-term debt	(169,987)		(87,218)

Stock repurchases	(14,960)		—

Taxes paid related to net-share settlement of equity awards	(830)		(2,526)

Other financing activities	(1,168)		(1,003)
Net cash used in financing activities	(98,340)		(90,747)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4,553		(530)
Net decrease in cash, cash equivalents and restricted cash	(58,642)		(141,538)
Cash, cash equivalents and restricted cash at the beginning of the year	172,881		333,111
Cash, cash equivalents and restricted cash at the end of the period	$	114,239	$	191,573

Balances per Condensed Consolidated Balance Sheets:
Cash and cash equivalents	$	95,542	$	190,005
Restricted cash included in prepaid expenses and other current assets	126		122
Restricted cash included in other assets (a)	18,571		1,446
Total cash, cash equivalents and restricted cash	$	114,239	$	191,573

Continued on next page

See accompanying notes to condensed consolidated financial statements.

Table of Content

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)


(in thousands)	Nine Months Ended
Supplemental cash flow information	September 30, 2025		September 30, 2024
Lease assets obtained in exchange for new lease liabilities	$	3,155	$	1,955
Cash interest payments	715		766
Cash income tax payments, net	3,820		4,580
Transfer of equipment from inventory to property and equipment, net (b)	3,199		1,655
Exchange of assets for investment	1,016		—

(a)The balance in restricted cash as of September 30, 2025 includes (1) $16.8 million of restricted cash as required by the indenture for the Convertible senior secured notes due 2030 and (2) guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The balance in restricted cash as of September 30, 2024 primarily relates to guarantees in the form of a standby letter of credit as security for a long-term real estate lease. Refer to Note 6 and Note 12 for further information.

(b) Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.

See accompanying notes to condensed consolidated financial statements.

Table of Content

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)


	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(in thousands)	Shares	Amount
Balance, December 31, 2024	135,510	$	136	$	1,593,366	$	(1,362,243)	$	(55,066)	$	176,193
Shares issued, vested and canceled under equity incentive plans	(53)	(1)		—		—		—		(1)
Shares withheld related to net-share settlement of equity awards	(96)	—		(285)		—		—		(285)

Stock-based compensation expense	—	—		3,666		—		—		3,666
Net loss attributable to 3D Systems Corp.	—	—		—		(36,986)		—		(36,986)
Pension plan adjustment	—	—		—		—		6		6


Foreign currency translation adjustment	—	—		—		—		3,046		3,046
Balance, March 31, 2025	135,361	135		1,596,747		(1,399,229)		(52,014)		145,639
Shares issued, vested and canceled under equity incentive plans	784	1		—		—		—		1
Shares withheld related to net-share settlement of equity awards	(158)	—		(320)		—		—		(320)

Stock-based compensation expense	—	—		(2,507)		—		—		(2,507)
Net income attributable to 3D Systems Corp.	—	—		—		104,436		—		104,436
Pension plan adjustment	—	—		—		—		14		14


Repurchase and retirements of common stock	(8,000)	(8)		(14,952)						(14,960)
Foreign currency translation adjustment	—	—		(132)		—		9,075		8,943
Balance, June 30, 2025	127,987	128		1,578,836		(1,294,793)		(42,925)		241,246
Shares issued, vested and canceled under equity incentive plans	365	—		—		—		—		—
Shares withheld related to net-share settlement of equity awards	(107)	—		(225)		—		—		(225)

Stock-based compensation expense	—	—		1,198		—		—		1,198
Net loss attributable to 3D Systems Corp.	—	—		—		(18,053)		—		(18,053)



Foreign currency translation adjustment	—	—		—		—		(3,066)		(3,066)
Balance, September 30, 2025	128,245	$	128	$	1,579,809	$	(1,312,846)	$	(45,991)	$	221,100

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

Condensed Consolidated Statements of Stockholders' Equity (continued)

(Unaudited)


	Common Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
(in thousands)	Shares	Amount
Balance, December 31, 2023	133,619	$	134	$	1,577,519	$	(1,106,650)	$	(44,250)	$	426,753
Shares issued, vested and canceled under equity incentive plans	534	—		—		—		—		—
Shares withheld related to net-share settlement of equity awards	(350)	—		(1,710)		—		—		(1,710)

Stock-based compensation expense	—	—		6,591		—		—		6,591
Net loss attributable to 3D Systems Corp.	—	—		—		(16,001)		—		(16,001)
Pension plan adjustment	—	—		—		—		(7)		(7)

Redeemable non-controlling interest redemption value in excess of carrying value	—	—		(75)		—		—		(75)
Foreign currency translation adjustment	—	—		—		—		(7,186)		(7,186)
Balance, March 31, 2024	133,803	134		1,582,325		(1,122,651)		(51,443)		408,365
Shares issued, vested and canceled under equity incentive plans	8	—		—		—		—		—
Shares withheld related to net-share settlement of equity awards	(224)	—		(793)		—		—		(793)

Stock-based compensation expense	—	—		2,711		—		—		2,711
Net loss attributable to 3D Systems Corp.	—	—		—		(27,258)		—		(27,258)
Pension plan adjustment	—	—		—		—		(2)		(2)

Redeemable non-controlling interest redemption value in excess of carrying value	—	—		(98)		—		—		(98)
Foreign currency translation adjustment	—	—		—		—		(1,196)		(1,196)
Balance, June 30, 2024	133,587	134		1,584,145		(1,149,909)		(52,641)		381,729
Shares issued, vested and canceled under equity incentive plans	1,248	1		—		—		—		1
Shares withheld related to net-share settlement of equity awards	(9)	—		(23)		—		—		(23)

Stock-based compensation expense	—	—		4,952		—		—		4,952
Net loss attributable to 3D Systems Corp.	—	—		—		(178,627)		—		(178,627)
Pension plan adjustment	—	—		—		—		13		13

Redeemable non-controlling interest redemption value in excess of carrying value	—	—		(163)		—		—		(163)
Foreign currency translation adjustment	—	—		—		—		10,150		10,150
Balance, September 30, 2024	134,826	$	135	$	1,588,911	$	(1,328,536)	$	(42,478)	$	218,032

See accompanying notes to condensed consolidated financial statements.

Table of Content

NOTE 1 - BASIS OF PRESENTATION

3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions (which includes dental, medical devices, personalized health services and regenerative medicine) and Industrial Solutions (which includes aerospace, defense, transportation and general manufacturing). We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

Consolidated Entities

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all majority-owned and wholly-owned subsidiaries and entities in which a controlling interest is maintained. Intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current year presentation. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 ( the “2024 Annual Report on Form 10-K”). The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the Company's financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.

Our annual reporting period is the calendar year. The Company's results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the full year.

Summary of Significant Accounting Policies

There have been no significant changes to our accounting policies since those disclosed in the Company's 2024 Annual Report on Form 10-K.

Finance Leases

As of September 30, 2025 and December 31, 2024, short-term finance lease obligations of $1.6 million and $1.5 million, respectively, are included in Accrued and other liabilities, and long-term finance lease obligations of $9.8 million and $10.5 million, respectively, are included in Other liabilities on our Condensed Consolidated Balance Sheets.

Amortization of Intangible Assets

Amortization expense related to our intangible assets with finite lives was $0.5 million and $1.7 million for the three and nine months ended September 30, 2025, respectively, and $7.9 million and $12.1 million for the three and nine months ended September 30, 2024, respectively.

Goodwill

For the three and nine months ended September 30, 2025, there were no impairment charges related to goodwill.

During the second quarter of 2025, management identified a triggering event for the Healthcare reporting unit resulting from macroeconomic uncertainties, updates to strategic plans and restructuring initiatives, and a decline in the Company’s stock price. Accordingly, an interim goodwill impairment assessment was performed. Based on the results of the quantitative test, no impairment was identified, as the estimated fair value of the reporting unit exceeded its carrying value.

Table of Content

The fair value of the reporting unit was determined using a combination of income and market approaches. The income approach was based on discounted cash flow projections, while the market approach utilized information from comparable companies. Significant assumptions included projected revenue growth rates and a discount rate of 26.2%, derived from the Company’s weighted average cost of capital, reflecting market, industry, and risk factors. This assessment represents a Level 3 measurement due to the use of unobservable inputs and significant management judgment.

Although no impairment was identified during the interim test, future changes in operating results, cash flows, share price, market capitalization, or discount rates could adversely affect the implied fair value of goodwill and may result in future impairment charges.

For the three and nine months ended September 30, 2024, the Company recognized a goodwill impairment charge of $101.4 million related to the Healthcare Solutions reporting unit. This charge resulted from an interim impairment test, which indicated the reporting unit's carrying value exceeded its fair value due to revised long-range cash flow forecasts prepared during the Company’s annual planning process. The impairment is included in “Asset impairment charges” in the Condensed Consolidated Statements of Operations.

Long-Lived Asset Impairments

For the three and nine months ended September 30, 2025, there were no impairment charges related to long-lived assets.

For the three and nine ended September 30, 2024, the Company recorded an aggregate impairment charge of $42.3 million, within "Asset impairment charges" on our Condensed Consolidated Statements of Operations, as a result of concluding that the carrying value of the primary asset group underlying the Company's core operations exceeded the fair value of the asset group as of September 30, 2024. Of this amount, $31.2 million was allocated to intangible assets, resulting in reductions to the carrying values of customer relationships of $0.3 million, acquired technology of $23.2 million, and trade names of $7.7 million. An additional $5.9 million of the impairment charge related to property and equipment. The remaining $5.2 million impairment charge was allocated to right-of-use assets and reduced the carrying values of our operating lease right-of-use assets by $2.7 million and finance lease right-of-use assets by $2.5 million. The Company estimated the fair values of the intangible assets and right-of-use assets included in the asset group using the income approach and estimated the fair value of the property and equipment included in the asset group using the cost approach. The estimation of the fair values of all classes of long-lived assets to which the impairment charge has been allocated required the application of Level 3 valuation inputs (as defined in Note 13).

Recently Issued Accounting Standards Not Yet Adopted

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, while permitted to be adopted on a retrospective basis. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Upon adoption, this ASU is expected to result in the inclusion of additional tax-related disclosures in the footnotes to our consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of the ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is currently in the process of evaluating the effects of this ASU on our consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets." The ASU introduces a practical expedient that allows entities to assume that current conditions as of the balance sheet date will remain unchanged over the remaining life of eligible accounts receivable and contract assets. Under this expedient, entities are not required to forecast future changes in conditions for these assets; however, they must continue to consider customer-specific information and any known or expected deviations from current conditions. This update is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.

Table of Content

In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software." The ASU revises the accounting and disclosure requirements for internally developed software, including moving website development guidance from ASC 350-50 to ASC 350-40, eliminating the use of development stages, and introducing new capitalization criteria based on (1) management’s authorization and funding commitment, and (2) the probability of project completion and intended functionality. It also includes guidance for assessing significant development uncertainty. This update is effective for annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.

NOTE 2 - REVENUES

Contract Assets

In certain circumstances, contract assets are recorded to include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customers, and right to payment is subject to contractual performance obligations rather than subject only to the passage of time. Contract assets were $0.2 million and $0.3 million as of September 30, 2025 and December 31, 2024, respectively, and are included in Accounts receivable, net on the accompanying Condensed Consolidated Balance Sheets.

Contract Liabilities

Our contract liabilities consist of deferred revenue generally related to maintenance and service contracts, post-sale support and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. The non-current portion of deferred revenue is recorded within Other liabilities on our Condensed Consolidated Balance Sheets.

Our contract liabilities consisted of the following:


(in thousands)	September 30, 2025		December 31, 2024
Deferred revenue, current and customer deposits	$	27,781	$	32,010
Deferred revenue, noncurrent	3,989		2,259
Total contract liabilities	$	31,770	$	34,269

During the three and nine months ended September 30, 2025, the Company recognized $5.1 million and $30.2 million, respectively, of revenue related to the Company's contract liabilities at December 31, 2024. The change in contract liabilities from December 31, 2024 to September 30, 2025 was primarily due to the timing of cash receipts and sales of extended service contracts.

Collaborative Arrangements

The Company enters into collaborative arrangements with customers that provide for cost reimbursement of certain expenses and potential milestone payments.

The Company recognized $0.8 million and $7.2 million in product revenue, and $2.3 million and $6.1 million in product cost of sales, related to collaborative arrangements during the three and nine months ended September 30, 2025, respectively. For the three months ended September 30, 2025, product revenue was lower than the associated cost of sales due to a revision of the transaction price for a specific collaborative agreement, which negatively impacted contract profitability.

For the three and nine months ended September 30, 2024, the Company recognized $2.0 million and $5.8 million in product revenue and $1.4 million and $4.8 million in product cost of sales, respectively, related to collaborative arrangements.

Remaining Performance Obligations

Remaining performance obligations represent the transaction price allocated to performance obligations that are unsatisfied as of the end of the period. As of September 30, 2025, the Company had $6.7 million of remaining performance obligations, primarily related to maintenance and service contracts, post-sale support and extended warranties. We expect approximately 96% to be recognized as revenue within the next two years, and the remaining thereafter. We have excluded performance obligations with an original expected duration of one year or less.

Table of Content

Revenue Concentration

Revenue, disaggregated by the geographic region in which a sale originated, was as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Americas	$	52,239	$	66,500	$	159,491	$	193,285
EMEA	32,592		36,864		99,167		108,300
APAC	6,418		9,576		21,969		27,512
Total	$	91,249	$	112,940	$	280,627	$	329,097


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
United States (included within Americas)	$	51,855	$	65,471	$	157,386	$	190,796
Germany (included within EMEA)	13,377		17,808		43,239		49,353

For the three and nine months ended September 30, 2025, one customer accounted for 11.2% and 10.9% of our consolidated revenue, respectively. For the three and nine months ended September 30, 2024, one customer accounted for 19.9% and 17.4% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer.

NOTE 3 - INVENTORIES


(in thousands)	September 30, 2025		December 31, 2024
Raw materials	$	47,793	$	43,138
Work in process	1,772		3,481
Finished goods and parts	82,904		71,911
Total inventories	$	132,469	$	118,530

NOTE 4 - DIVESTITURES

In September 2025, the Company entered into a definitive agreement for the sale of its 3DXpert and Oqton businesses to Hubb Global Holdings, LLC for $3.5 million plus a revenue-based royalty of up to $12.9 million. 3DXpert and Oqton are included in our Industrial Solutions segment.

On October 31, 2025, the Company completed the sale of the 3DXpert and Oqton businesses, subject to customary adjustments.

The Company determined that the associated assets and liabilities met the held for sale criteria during September 2025, with approval by the Company's Board of Directors and the signing of the purchase agreement. Accordingly, the Company classified $1.6 million of assets and $5.1 million of liabilities as held for sale in the Company’s Condensed Consolidated Balance Sheet as of September 30, 2025. No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been classified as a discontinued operation in the accompanying condensed consolidated financial statements, as the sale of 3DXpert and Oqton does not constitute a strategic shift that would have a major effect on the Company’s operations.

Table of Content

The following table summarizes the assets and liabilities of 3DXpert and Oqton that have been classified as held for sale at September 30, 2025:


(in thousands)	September 30, 2025
Assets


Prepaid expenses and other current assets	$	294
Total current assets held for sale	294
Property and equipment, net	77
Intangible assets, net	3
Other assets	1,187
Total assets held for sale	$	1,561
Liabilities
Accounts payable	$	149
Accrued and other liabilities	529
Customer deposits	50
Deferred revenue	2,941
Total current liabilities held for sale	3,669
Other liabilities	1,408
Total liabilities held for sale	$	5,077

In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments under the Asset Purchase Agreement and Business Transfer Agreement. The Company recorded a pre-tax gain of $125.7 million from the sale of Geomagic in the nine months ended September 30, 2025.

No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying condensed consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.

The Company determined that the associated assets and liabilities met the held for sale criteria in December 2024. The following table summarizes the assets and liabilities of Geomagic:


(in thousands)	December 31, 2024
Assets
Accounts receivable, net	$	765

Prepaid expenses and other current assets	47
Total current assets held for sale	812

Intangible assets, net	917

Other assets	1,447
Total assets held for sale	$	3,176
Liabilities


Accounts payable	$	491
Accrued and other liabilities	303

Deferred revenue	7,197
Total current liabilities held for sale	7,991

Other liabilities	2,260
Total liabilities held for sale	$	10,251

Table of Content

NOTE 5 - INVESTMENTS AND NOTE RECEIVABLE

The Company holds various equity investments, which are recorded in Other assets on our Condensed Consolidated Balance Sheets. The following table summarizes our investment balances:


(in thousands)	September 30, 2025		December 31, 2024
Equity investments under the equity method of accounting	$	2,031	$	5,051
Equity investments without readily determinable fair values	21,712		20,696

Total equity investments	$	23,743	$	25,747

During the second quarter of 2025, the Company purchased additional shares of an equity method investment in Enhatch Inc. ("Enhatch") for $0.9 million. As of September 30, 2025, the Company owns approximately 79% of Enhatch's outstanding common stock and approximately 46% of Enhatch's outstanding voting stock.

During the second quarter of 2025, the Company entered into an agreement with GenesisTissue Inc. ("GenesisTissue") to obtain shares of common stock in exchange for the sale of certain assets. As of September 30, 2025, the Company owns approximately 8% of GenesisTissue's outstanding common stock. The Company has accounted for its investment in GenesisTissue on a cost basis, subject to assessment for impairment, as (1) the fair value of GenesisTissue's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The carrying value of the equity investment without a readily determinable fair value is $1.0 million as of September 30, 2025.

Note Receivable - Related Party

In February 2023, we became a shareholder in a joint venture, National Additive Manufacturing Innovation ("NAMI") Joint Venture, formed with the Saudi Arabian Industrial Investments Company ("Dussur") for purposes of expanding the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa.

In December 2024, the Company entered into a short-term, non-interest bearing loan agreement with NAMI whereby NAMI borrowed $2.0 million to finance its working capital and capital expenditures requirements. The loan originally matured on June 30, 2025. During the quarter ended September 30, 2025, the parties amended the loan agreement to extend the maturity date to June 30, 2026, and increase the total related party note receivable to $4.4 million.

The loan is recorded at cost, which approximates fair value as of September 30, 2025. The carrying value of the related party note receivable was $4.4 million and $2.0 million as of September 30, 2025 and December 31, 2024, respectively. The note receivable is reported in Prepaid expenses and other current assets, on our Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024.

Additionally, during the three and nine months ended September 30, 2025 and 2024, the Company entered into related party transactions with certain of our equity investments in the ordinary course of business. These transactions, and the related payable and receivable balances, were not material.

Other Asset

In February 2025, the Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, EVP, Chief Technology Officer for the Company's Regenerative Medicine business and a related party of the Company. The financing is recorded in Other assets on our Condensed Consolidated Balance Sheets as of September 30, 2025.

Variable Interest Entities ("VIEs")

The Company concluded that three of its investments are VIEs. These investments are not consolidated as we concluded that the Company is not the primary beneficiary. As of September 30, 2025, our maximum exposure to losses associated with the VIEs is limited to the $21.4 million carrying value of our investments in the VIEs, $4.4 million of which is included in Prepaid expenses and other current assets, with the remaining in Other assets on our Condensed Consolidated Balance Sheets. We have no other investments in unconsolidated entities that have been determined to be a VIE.

Table of Content

NOTE 6 - BORROWINGS

Convertible Senior Notes

Convertible senior secured notes due 2030

Pursuant to an indenture dated June 23, 2025 (the "2030 Indenture"), the Company issued $92.0 million aggregate principal amount of 5.875% convertible senior secured notes due 2030 (the "2030 Notes") in a private placement to a limited number of qualified institutional buyers. The net proceeds from the 2030 Notes, along with $78.0 million of cash on hand, were used to repurchase an aggregate principal amount of $179.7 million of the Company's outstanding 0% convertible senior notes due 2026 (the “2026 Notes”).

The 2030 Notes are senior secured obligations, guaranteed by certain U.S. subsidiaries of the Company (the "Note Parties"), and bear interest semiannually at a rate of 5.875%, payable on June 15 and December 15 of each year, beginning December 15, 2025. The 2030 Notes are secured on a first-priority basis by substantially all assets of the Note Parties, subject to certain exceptions (including with respect to the intellectual property of the Note Parties; provided that, certain breaches by the Company or any of its subsidiaries of the limitation on liens covenant in the 2030 Indenture with respect to liens on its intellectual property will cause the 2030 Notes to automatically become secured by a prior security interest in all the intellectual property of the Note Parties). The 2030 Indenture also includes certain financial covenants, including a requirement for the Note Parties to maintain certain minimum cash, accounts receivable and inventory balances each quarter. As of the last day of each fiscal quarter, the Note Parties must maintain at least $40.0 million in qualified cash; maintain a combined minimum of $75.0 million in accounts receivable and inventory; and maintain at least $16.8 million in restricted cash until the remaining 2026 Notes is paid.

The initial conversion rate was 445.6328 shares per $1,000 principal amount, equivalent to a conversion price of approximately $2.24 per share, which reflected a 20% premium over the $1.87 closing price of the Company’s common stock on June 17, 2025. The 2030 Notes are set to mature on June 15, 2030, unless earlier converted, redeemed, or repurchased. The 2030 Notes will be convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the election of the Company.

Holders of the 2030 Notes have a one-time put right on June 23, 2028, to require the Company to repurchase all or a portion of their 2030 Notes for cash at 100% of the principal amount, plus accrued and unpaid interest. Additionally, upon a fundamental change (as defined in the 2030 Indenture), holders may require repurchase on the same terms. The Company is required to increase the conversion rate for holders who convert in connection with certain fundamental changes or in connection with a redemption.

On or after June 23, 2028 and prior to the 41st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable, in whole or in part, at the Company's option, for cash, provided that the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period, as described in the 2030 Indenture.

Convertible senior notes due 2026

The 2026 Notes were issued pursuant to an indenture dated November 16, 2021 (the “2026 Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee (the “Trustee”), in an initial aggregate principal amount of $460.0 million. Although the 2026 Notes do not bear regular interest and their principal does not accrete, they have an annual effective interest rate of 0.594%, reflecting original issue discounts, commissions, and offering expenses. The 2026 Notes had an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the 2026 Indenture. The 2026 Notes are scheduled to mature on November 15, 2026, unless earlier redeemed, repurchased, or converted in accordance with their terms.

Prior to August 15, 2026, the 2026 Notes will only be convertible upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

The 2026 Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period of time.

Table of Content

The Company incurred debt issuance cost accretion related to the 2026 Notes and the 2030 Notes of $0.3 million and $1.0 million for the three and nine months ended September 30, 2025, respectively. The Company incurred debt issuance cost accretion relating to the 2026 Notes of $0.3 million and $1.1 million for the three and nine months ended September 30, 2024, respectively.

The following tables summarize the detail of the Company's convertible senior notes:


(in thousands)	Outstanding Principal		Unamortized Deferred Issuance Costs		Carrying Value
September 30, 2025
0% Convertible senior notes due 2026	$	34,717	$	(232)	$	34,485
5.875% Convertible senior notes due 2030	92,030		(3,915)		88,115
Outstanding convertible notes	$	126,747	$	(4,147)	$	122,600

(in thousands)	Outstanding Principal		Unamortized Deferred Issuance Costs		Carrying Value
December 31, 2024
0% Convertible senior notes due 2026	$	214,378	$	(2,383)	$	211,995
Outstanding convertible notes	$	214,378	$	(2,383)	$	211,995

As of September 30, 2025, the Company was in compliance with all of the covenants included in the 2026 Indenture and 2030 Indenture.

Debt Extinguishment

In June 2025, the Company used the proceeds of $92.0 million from the issuance of the 2030 Notes, along with $78.0 million of cash on hand, to repurchase an aggregate principal amount of $179.7 million of its outstanding 2026 Notes, which were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $8.2 million, after transaction expenses and the write-off of $1.5 million in related debt issuance costs. The gain is reported in Other income (loss), net on the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2025.

In March 2024, the Company repurchased $110.5 million of the 2026 Notes for $87.2 million, including transaction expenses. The repurchased 2026 Notes were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $21.5 million, after transaction expenses and the write-off of $1.8 million in related debt issuance costs. The gain is reported in Other income (loss), net on the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2024.

NOTE 7 - STOCK-BASED COMPENSATION

2015 Incentive Plan

The Company is authorized to grant shares of restricted stock, restricted stock units (“RSUs”), stock appreciation rights, cash incentive awards and options to purchase shares of common stock to employees and non-employee directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance awards and market-based awards.

During the nine months ended September 30, 2025, the Company granted 810 thousand performance-based RSUs ("PSUs") to employees with a weighted-average grant date fair value of $0.47 per share. The PSUs are subject to three-year cliff vesting. Vesting is contingent upon the continued service and market conditions that are met based on annualized stock price growth goals. During the nine months ended September 30, 2025, the Company granted 2,103 thousand shares of restricted stock to employees with a weighted-average grant date fair value of $2.38 per share. The restricted stock awards are subject to time-based vesting conditions and generally vest ratably over 3 years.

Table of Content

Stock-Based Compensation Activity and Expense

The following table shows the stock-based compensation expense recognized:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Stock-based compensation expense	$	1,198	$	3,666	$	1,805	$	17,339

During the nine months ended September 30, 2025, the Company recognized a one-time reversal of $6.6 million in previously recognized compensations expense, primarily due to the forfeiture of PSUs that did not meet performance conditions and the cancellation of 2025 annual incentive compensation.

Stock-based compensation expense recognized for the three and nine months ended September 30, 2024 includes $0.8 million and $3.1 million, respectively, of accrued expense pertaining to annual incentive compensation expected to be settled in shares of common stock.

As of September 30, 2025, there was $11.2 million of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 2 years.

dp polar Earnout

On October 4, 2022 the Company acquired dp polar. The acquisition agreement included an earnout arrangement for $2.2 million incremental to the acquisition purchase price, which would be settled via the issuance of 250 thousand shares of the Company's common stock. During the second quarter of 2025, the dp polar earnout was settled through the issuance of 250 thousand shares of the Company's common stock. There was no stock-based compensation expense related to the dp polar earnout arrangement for the three and nine months ended September 30, 2025. There was no stock-based compensation expense related to the dp polar earnout arrangement for the three months ended September 30, 2024. For the nine months ended September 30, 2024, the expense was $1.0 million.

NOTE 8 - INCOME TAXES

We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Accordingly, we have used a year-to-date methodology in determining the effective tax rate for the three and nine months ended September 30, 2025 and 2024.

For the three and nine months ended September 30, 2025, the Company's effective tax rate was 13.6% and 14.6%, respectively. For the three and nine months ended September 30, 2024 the Company’s effective tax rate was 2.4% and 1.1%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three and nine months ended September 30, 2025 and 2024 were primarily driven by the recognition of a full deferred tax asset valuation allowance in various jurisdictions in both years. Additionally, the nine months ended September 30, 2025, were impacted by a gain recognized in connection with the divestiture of Geomagic and some foreign return to provision adjustments recorded in the quarter.

On July 4, 2025, the U.S. enacted H.R. 1, commonly referred to as the One Big Beautiful Bill Act (OBBBA). The Company has evaluated the impacts of the new legislation and there is no material impact on the condensed consolidated financial statements.

NOTE 9 - NET (LOSS) INCOME PER SHARE

Basic net (loss) income per common share is calculated by dividing net (loss) income attributable to 3D Systems’ common stock by the weighted average number of shares of common stock outstanding during the applicable period. Diluted net (loss) income per common share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such case when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date.

Table of Content


	Three Months Ended				Nine Months Ended
(in thousands, except per share amounts)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Numerator (basic):
Net (loss) income attributable to 3D Systems Corporation	$	(18,053)	$	(178,627)	$	49,397	$	(221,886)
Redeemable non-controlling interest redemption value in excess of carrying value	—		(163)		—		(336)
Net (loss) income attributable to 3D Systems' common stock shareholders	$	(18,053)	$	(178,790)	$	49,397	$	(222,222)
Numerator (diluted):
Net (loss) income attributable to 3D Systems' common stock shareholders	$	(18,053)	$	(178,790)	$	49,397	$	(222,222)
Add back: Interest on 2030 Notes	—		—		1,455		—
Net (loss) income attributable to 3D Systems' common stock shareholders plus assumed conversions	$	(18,053)	$	(178,790)	$	50,852	$	(222,222)

Denominator:
Basic weighted average common shares outstanding(a)	125,273		132,235		129,979		131,621
Effect of Dilutive securities:
Restricted stock and RSUs	—		—		1,480		—
Conversion of 2030 Notes	—		—		46,938		—
Diluted weighted average common shares outstanding	125,273		132,235		178,397		131,621

Net (loss) income per common share:
Basic	$	(0.14)	$	(1.35)	$	0.38	$	(1.69)
Diluted	$	(0.14)	$	(1.35)	$	0.29	$	(1.69)

Anti-dilutive shares	5,532		4,856		2,992		4,612

(a) For the three and nine months ended September 30, 2025, includes 250 thousand shares of common stock issued in April 2025 in connection with the dp polar earnout arrangement.

The anti-dilution table above excludes shares issued in connection with the settlement of accrued incentive compensation. In the three and nine months ended September 30, 2025 and the three months ended September 30, 2024, there were no shares related to the payment of accrued incentive compensation. In the nine months ended September 30, 2024 there were 826 thousand shares related to the payment of accrued incentive compensation. These estimates are based on the liabilities recorded as of September 30, 2025 and September 30, 2024, under the fiscal year 2025 and 2024 incentive compensation arrangements, respectively, divided by the Company’s year-to-date average share price of $2.41 for 2025 and $3.77 for 2024.

Diluted income per common share was computed using the treasury stock method for restricted shares and RSUs and the if-converted method for convertible debt.

Share Repurchases

On June 23, 2025, 3D Systems repurchased 8.0 million shares of its outstanding common stock at a price of $1.87 per share, which was equal to the closing price of the common stock on the New York Stock Exchange on June 17, 2025. The share repurchase was executed concurrently with the issuance of the 2030 Notes (refer to Note 6).

The share repurchase was approved by the Company’s Board of Directors in connection with the broader refinancing transaction. It was structured to mitigate potential dilution associated with the issuance of the 2030 Notes and was funded as part of the same transaction that retired a significant portion of the Company’s 2026 Notes at a discount to par. The Company retired its common stock upon repurchase.

Table of Content

NOTE 10 - ACCUMULATED OTHER COMPREHENSIVE LOSS

The changes in the balances of accumulated other comprehensive loss, net of tax, by component are as follows:


	Three Months Ended September 30, 2025
(in thousands)	Foreign currency translation adjustment		Defined benefit pension plan		Total
Balance, June 30, 2025	$	(43,096)	$	171	$	(42,925)
Other comprehensive loss	(3,066)		—		(3,066)
Balance, September 30, 2025	$	(46,162)	$	171	$	(45,991)

	Three Months Ended September 30, 2024
(in thousands)	Foreign currency translation adjustment		Defined benefit pension plan		Total
Balance, June 30, 2024	$	(52,946)	$	305	$	(52,641)
Other comprehensive income	10,150		13		10,163
Balance, September 30, 2024	$	(42,796)	$	318	$	(42,478)


	Nine Months Ended September 30, 2025
(in thousands)	Foreign currency translation adjustment		Defined benefit pension plan		Total
Balance, December 31, 2024	$	(55,217)	$	151	$	(55,066)
Other comprehensive income	9,055		20		9,075
Balance, September 30, 2025	$	(46,162)	$	171	$	(45,991)

	Nine Months Ended September 30, 2024
(in thousands)	Foreign currency translation adjustment		Defined benefit pension plan		Total
Balance, December 31, 2023	$	(44,564)	$	314	$	(44,250)
Other comprehensive income	1,768		4		1,772
Balance, September 30, 2024	$	(42,796)	$	318	$	(42,478)

NOTE 11 - SEGMENT INFORMATION

Our chief operating decision maker ("CODM"), who is our President and Chief Executive Officer, is responsible for reviewing segment performance and making decisions regarding resource allocation. Our CODM regularly reviews the results of our business through two reportable segments: Healthcare Solutions and Industrial Solutions, which are based on the industry verticals they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing.

The CODM evaluates each segment’s performance based on gross profit, which is also utilized in the annual budgeting and forecasting processes, as well as in quarterly reviews of budget-to-actual results and period-over-period variances. Beginning during the quarter ended December 31, 2024, all internal segment reporting and discussions with the CODM have been based on segment gross profit. Prior period segment results have been revised to conform with current period presentation.

The CODM does not review disaggregated asset information on the basis of the Company's segments; therefore, such information is not presented.

Table of Content

Revenue, cost of sales and gross profit for each of our reportable segments were as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Revenue:
Healthcare Solutions	$	42,787	$	55,056	$	129,123	$	149,369
Industrial Solutions	48,462		57,884		151,504		179,728
Total revenue	91,249		112,940		280,627		329,097
Cost of sales:
Healthcare Solutions	26,367		31,734		76,297		86,630
Industrial Solutions	35,451		39,493		106,060		112,734
Total cost of sales	61,818		71,227		182,357		199,364
Gross profit:
Healthcare Solutions	16,420		23,322		52,826		62,739
Industrial Solutions	13,011		18,391		45,444		66,994
Total gross profit	29,431		41,713		98,270		129,733
Selling, general and administrative	34,716		57,974		118,624		166,772
Research and development	16,025		20,764		53,069		66,260
Asset impairment charges	—		143,733		—		143,733
Foreign exchange gain (loss), net	2,623		(1,960)		2,171		(774)
Interest income	784		1,550		3,454		5,800
Interest expense	(1,924)		(606)		(3,202)		(1,944)
Gain on disposition	—		—		125,681		—
Other income (loss), net	475		(51)		7,335		21,719
Net (loss) income before income taxes	$	(19,352)	$	(181,825)	$	62,016	$	(222,231)

Depreciation and amortization included in the measurement of gross profit by segment were as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Depreciation and amortization:
Healthcare Solutions	$	1,385	$	1,289	$	4,070	$	4,009
Industrial Solutions	$	493	$	726	$	1,786	$	2,257

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company has certain purchase commitments under agreements with remaining terms in excess of one year primarily related to printer assemblies, inventory, capital expenditures, and software licenses. As of September 30, 2025, such purchase commitments totaled $17.4 million, with $9.0 million of the purchase obligations expected to be due within the next twelve months.

Indemnification

In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments that we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Table of Content

Other Commitments

Government Settlement

In October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce (“BIS”). In February 2023, the Company settled these matters with the U.S. Department of Justice (“DOJ”), DDTC and BIS. As a part of these settlement agreements, the Company agreed to pay $15.0 million in civil monetary penalties to these agencies, with an additional $10.0 million suspended penalty amount to be allocated to remedial compliance measures required by DDTC. The penalty amounts subject to payment were broken down as follows: DDTC, $10.0 million (payable in three installments over a three-year period); BIS, $2.8 million; and DOJ, $2.3 million.

During the three months ended March 31, 2025, we paid the final installment penalty of $3.0 million in accordance with the DDTC settlement agreement. The original $10.0 million suspended penalty has not been recognized as a liability, as it will be recognized as incurred for remedial compliance measures during the three-year term of the settlement agreement. The application of the Company’s spend on remedial compliance measures as a reduction to the original $10.0 million suspended penalty must be approved by DDTC, which approval will be sought on an annual basis in accordance with the terms of the settlement agreement. As of September 30, 2025, the approved suspended penalty balance remaining is $5.1 million. Any portion not expended for compliance measures at the end of the three-year term of the settlement agreement will be paid by the Company to DDTC.

Letter of Credit

On June 2, 2023, we issued $1.2 million of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has a maturity date in June 2026 and includes automatic one-year extensions, which are not to continue beyond July 1, 2033. As of September 30, 2025, the letter of credit has been reduced to $0.8 million. We have not recorded any liability for this guarantee, as we believe that the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash and included in Other assets on our Condensed Consolidated Balance Sheets.

Litigation

SEC Investigation

On April 15, 2022, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, allegations that had been brought against the Company in a securities class action lawsuit that was brought against the Company in 2021 and settled in January 2024. The Company has subsequently received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The most recent SEC subpoena was received by the Company in August 2024, and requested additional documents and information relating to its continuing investigation of the Company. The Company completed its submission of this additional information to the SEC by the end of November 2024. The Company is continuing to cooperate with the SEC in connection with its formal investigation.

Termination of Volumetric Milestones Related to Potential Earnout Payments

Following the acquisition of Volumetric in 2021, the Company could have been required to pay up to $355.0 million of acquisition-related earnout payments to the former owners of Volumetric if the Company was to achieve seven non-financial, science-based milestones prior to either December 31, 2030 or December 31, 2035. Due to the loss of funding from the Company's key strategic partner for kidney and liver research and development efforts, the Company notified the former owners of Volumetric on February 24, 2024 that it was terminating the four milestones that related to those kidney and liver research and development efforts, as achievement was no longer financially viable. As a result of the termination of the four milestones, the Company's maximum liability for acquisition-related earnout payments was reduced to $175.0 million, which would have been payable if each of the three remaining non-financial, science-based milestones was achieved within the timeframes set forth in the Volumetric acquisition agreement.

On March 29, 2024, the former owners of Volumetric notified the Company that they were initiating dispute resolution under the provisions of the acquisition agreement in an effort to recover the $355.0 million. The parties did not reach a resolution during the 30-day negotiation period following this notice and entered into non-binding mediation in accordance with the terms of the acquisition agreement.

Table of Content

On April 29, 2024, two key employees from Volumetric ("Volumetric Key Employees"), who were required to be employed at the time of achievement of each non-financial, science-based milestone outlined in the Volumetric acquisition agreement for each related acquisition earnout payment to become payable, resigned from their positions with the Company. As a result of the resignation of the Volumetric Key Employees, all parties to which the remaining three milestone-based earnout payments totaling $175.0 million were potentially payable were notified that such amount was no longer eligible to be earned. While the Volumetric Key Employees claim that their terminations were for good reason, which would preserve the rights to milestone-based earnout payments under the Volumetric acquisition agreement, the Company vigorously denies this claim. Presently, no lawsuit has been filed by the former owners of Volumetric to which milestone-based earnout payments were potentially payable, and there is no reasonable estimate or range of estimates of potential financial liability associated with this matter. On August 21, 2024, the Company proposed a settlement of $1.8 million with the former Volumetric shareholders and Volumetric Key Employees during mediation and this amount is recorded within Accrued and other liabilities on our Condensed Consolidated Balance Sheets as of September 30, 2025. The former Volumetric shareholders have not responded to the settlement offer. On December 13, 2024, the Company received a Notice of Claim for Indemnification from VBI Stockholders’ Representative, LLC., which claims to be the successor Stockholders’ Representative under the acquisition agreement. The Notice repeated the former Volumetric shareholders’ and Volumetric Key Employees' claims of breach. On January 10, 2025, the Company served a Notice of Objection which denied all liability. The delivery of this Notice of Objection triggered a 45-day negotiation period under the terms of the acquisition agreement. As of the date of this filing, there have been no further developments regarding this matter.

Intrepid Automation

On May 19, 2021, 3D Systems, Inc. initiated a lawsuit in the Superior Court of the State of California for the County of San Diego against five former employees and Intrepid Automation, Inc. (collectively, the “Intrepid Parties”) alleging theft of trade secrets, unfair competition, breach of contract, and related claims (“2021 Lawsuit”). In June 2021, this lawsuit was removed to the United States District Court for the Southern District of California. In September 2022, the Intrepid Parties filed counterclaims against 3D Systems, Inc. In September 2022, the Company filed a motion to dismiss these counterclaims; this motion was granted in part in May 2023. The Intrepid Parties filed amended counterclaims in May 2023 alleging theft of trade secrets, fraudulent inducement, breach of contract, unfair competition, and related claims; this amended complaint sought damages in excess of $20 million as well as injunctive relief. These counterclaims were partially dismissed in March 2024 in response to a second motion to dismiss filed by the Company. The parties filed motions for summary judgment in April and May 2024. In March 2025, the Court granted the Intrepid Parties’ motion, dismissing the Company’s claims against the Intrepid Parties, but denied the Company’s motion for summary judgment with respect to the counterclaims brought by the Intrepid Parties in the 2021 Lawsuit. On April 17, 2025, the Company filed motions asking the Court to reconsider its dismissal of the Company's claims or granting a partial final judgment so that the Company may appeal the dismissal.

On December 4, 2024, Intrepid Automation, Inc. (“Intrepid”) filed a lawsuit in the United States District Court for the Southern District of California against 3D Systems Corporation and 3D Systems, Inc. alleging infringement of U.S. patents 11,014,301 and 11,338,511 (“2024 Lawsuit”); this complaint seeks unspecified damages and injunctive relief. In July 2025, the Company filed inter partes review (“IPR”) petitions against the asserted patents, and on July 16, 2025, the Company filed a motion to stay the 2024 Lawsuit pending resolution of the IPRs.

The Company intends to defend itself vigorously against the 2024 Lawsuit and the counterclaims in the 2021 Lawsuit.

Securities Class Action

The Company and certain of its executive offers were named as defendants in a putative securities class action filed on June 13, 2025 in the U.S. District Court for the District of Delaware. The action is styled Marcel F.M. Herbermann v. 3D Systems Corporation, et al., No. 1:25-cv-00734-GBW (D. Del.) (the “Securities Class Action”). The complaint in the Securities Class Action alleges defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. It was filed on behalf of stockholders who purchased the Company’s common stock from August 13, 2024 and May 12, 2025, and seeks monetary damages on behalf of the purported class. Within fourteen days of the entry of an Order appointing Lead Plaintiff and Lead Counsel, the Parties will submit a proposed scheduling Order for the filing of an amended complaint and Defendants’ responses thereto. The Company intends to defend itself and its executive officers vigorously.

Table of Content

Derivative Actions

The Company was named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the U.S. District Court for the District of South Carolina. The action styled Scanlon v. Graves, et al., No. 0:25-cv-07627-MGL (D.S.C.) (the “Scanlon Action”) was filed July 17, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breach of fiduciary duties, and unjust enrichment. The action styled Milligan v. Graves, et al., No. 0:25-cv-11177-MGL (D.S.C.) (the “Milligan Action”), was filed August 18, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, breach of fiduciary duties, aiding and abetting breach of fiduciary duty, unjust enrichment, waste of corporate assets, and for contribution under Section 10(b) and 21D of the Securities Exchange Act of 1934. The action styled Stoopler v. Graves, et al., No. 0:25-cv-12637-MGL, was filed on September 20, 2025, and asserts claims for breach of fiduciary duties, unjust enrichment, and contribution and indemnification under Sections 10(b) and 21D of the Exchange Act. The Milligan and Scanlon Actions were consolidated on September 16, 2025.

The Company was also named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the South Carolina Court of Common Pleas for the 16th Circuit, York County. The action styled Fernicola v. Graves, et al., No. 2025CP4602544 (S.C.), Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Fernicola Action”) was filed June 27, 2025, and asserts claims for breach of fiduciary duties, gross mismanagement, waste of corporate assets, and unjust enrichment. The action styled Geza Bohus v. Graves, et al., No. 2025CP4603762 (S.C.), Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Bohus Action”) was filed on September 26, 2025, and asserts claims for breach of fiduciary duty and unjust enrichment.

The Company was also named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the U.S. District Court for the District of Delaware. The action styled Ataii v. Graves, et al., No. 1:25-cv-01087-GBW (D. Del.) (the “Ataii Action”) was filed on August 29, 2025 and asserts claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, breach of fiduciary duties, unjust enrichment. The action styled Carter v. Graves, et al., No. 1:25-cv-01103-GBW (D. Del.) (the “Carter Action”), was filed on September 3, 2025, and asserts claims for breach of fiduciary duty, gross mismanagement, waste of corporate assets, unjust enrichment, and violation of Section 14(a) of the Exchange Act. The action styled Michaels v. Graves, et al., No. 1:25-cv-01176-GBW (D. Del.) (the “Michaels Action”) was filed on September 22, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act, violations of Section 20(a) of the Exchange Act, breach of fiduciary duties, and unjust enrichment. The Company intends to defend itself as well as its officers and directors vigorously.

We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.

Contingencies

Warranty

Changes in accrued product warranty liability balance are summarized as follows:


(in thousands)	September 30, 2025		September 30, 2024
Balance at beginning of period	$	2,650	$	2,106
Settlements made	(2,268)		(2,384)
Accruals for warranties issued	2,431		2,567
Balance at the end of period	$	2,813	$	2,289

Table of Content

NOTE 13 - FAIR VALUE MEASUREMENTS

Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:

•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.

•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

•Level 3 - One or more inputs are unobservable and significant.

Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Recurring Fair Value Measurements

The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:


(in thousands)			Fair Value Measurement Using (a)
September 30, 2025	Total Fair Value		Level 1		Level 2		Level 3


Money market funds	$	49,276	$	49,276	$	—	$	—

December 31, 2024


Money market funds	$	98,212	$	98,212	$	—	$	—

(a) There were no transfers among the levels within the fair value hierarchy during the nine months ended September 30, 2025 or the year ended December 31, 2024.

Cash equivalents, including money market funds, are valued utilizing the market approach for measuring the fair value of financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of September 30, 2025 and December 31, 2024 because of the relatively short duration of these instruments.

Fair Value of Financial Instruments

The following table summarizes the carrying amount and fair value of our financial instruments:


	September 30, 2025				December 31, 2024
(in thousands)	Carrying Amount		Fair Value		Carrying Amount		Fair Value
0% Convertible senior notes due 2026	$	34,485	$	30,759	$	211,995	$	189,409
5.875% Convertible senior secured notes due 2030	$	88,115	$	92,030	$	—	$	—

The estimated fair value of the 2026 Notes was determined using quoted market price in a market with limited activity, and is therefore classified as Level 2 in the fair value hierarchy. The estimated fair value of the 2030 Notes was based on par value, as there has been no market activity since issuance. As a result, the fair value of the 2030 Notes is classified as Level 3.

Nonrecurring Fair Value Measurements

During the three and nine months ended September 30, 2024, the Company recorded asset impairment charges related to property, plant, and equipment; intangible assets, goodwill, and right-of-use assets. The recognition of these impairment charges required the Company to measure the fair value of the reporting unit to which goodwill is assigned, the fair value of asset groups, and the fair values of the long-lived assets comprising the impaired asset groups using Level 3 inputs. Refer to Note 1 for additional details regarding the impairment charges recognized during the three and nine months ended September 30, 2024.

Table of Content

NOTE 14 - RESTRUCTURING AND EXIT ACTIVITIES COSTS

The Company incurs restructuring charges in connection with strategic initiatives and cost-reduction efforts aimed at optimizing business operations. A description of significant restructuring plans and other restructuring charges is provided below.

2025 Restructuring

In 2025, in response to continuing macroeconomic challenges impacting the Company’s financial performance, the Company implemented a series of cost savings and restructuring initiatives (the "2025 Restructuring Plan") as part of its ongoing multi-faceted transformation strategy. In March 2025, the Company authorized and began executing the next phase of its cost savings and restructuring initiative which includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities. In May 2025, the Company announced and began executing an incremental cost reduction initiative focused on labor force reductions in response to continued uncertainty in the economy and our industry and the related potential negative impact on our financial performance. These initiatives are expected to continue to deliver cost savings and improve cash flows in the second half of fiscal 2025.

The Company expects to incur approximately $8.5 million to $14.5 million in pre-tax restructuring charges, primarily related to employee severance and other one-time employee benefit costs. These charges are anticipated to consist largely of cash expenditures and are expected to be recognized primarily in 2025 and through the second fiscal quarter of 2026.

Restructuring and other related charges were as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025(a)		September 30, 2024(b)		September 30, 2025(a)		September 30, 2024(b)
Employee severance related	$	1,859	$	669	$	8,001	$	318
Facility exit and other related	—		—		—		489

Total	$	1,859	$	669	$	8,001	$	807

(a) Includes expenses related to the 2025 Restructuring Plan

(b) Includes expenses related to the 2023 Restructuring Plan (discussed below)

The restructuring and other related charges were primarily cash charges. These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Cost of sales	$	23	$	469	$	1,024	$	(523)
Selling, general, and administrative expenses	1,409		8		5,589		899
Research and development	427		192		1,388		431
Total	$	1,859	$	669	$	8,001	$	807

Restructuring and other related charges recorded in cost of sales by reportable segment were as follows:


	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Healthcare Solutions	$	23	$	469	$	535	$	(523)
Industrial Solutions	—		—		489		—
Total	$	23	$	469	$	1,024	$	(523)

The activity in the restructuring accrual related to the 2025 Restructuring Plan was as follows:


(in thousands)	Balance, December 31, 2024		Costs Incurred		Paid/Settled		Balance, September 30, 2025
Employee severance related	$	—	$	8,001	$	(5,085)	$	2,916

2023 Restructuring Plan

In 2023, the Company initiated a restructuring plan aimed at improving operational efficiency and driving long-term value creation (the "2023 Restructuring Plan"). Key initiatives included in-sourcing certain European metal printer platforms to the Company’s Riom, France facility, co-locating engineering and manufacturing functions to accelerate the development-to-production cycle, reducing headcount across all areas of the organization, and exiting select leased facilities to streamline the Company’s geographic footprint. Substantially all restructuring activities related to the 2023 Restructuring Plan were completed as of the year ended December 31, 2024.

Table of Content

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of management and is intended to help the reader understand the results of operations and financial condition of the Company. Our MD&A should be read in conjunction with our MD&A and Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Annual Report on Form 10-K") and our Condensed Consolidated Financial Statements as of and for the three and nine months ended September 30, 2025 included in this Form 10-Q.

Information Relating to Forward-Looking Statements

Certain statements contained in this MD&A may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed, or implied by, such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include without limitation:

•impact on our business as a result of macroeconomic events and other geopolitical risks, recession, supply chain disruptions, inflation, interest rates and foreign exchange volatility;

•our ability to deliver products that meet changing technology and customer needs;

•our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;

•our ability to realize anticipated benefits for future dispositions;

•impact of future write-off or write-downs of goodwill and intangible assets;

•the concentration of revenue and credit risk exposure from our largest customer;

•our ability to acquire and enforce intellectual property rights and defend such rights against third-party claims;

•our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;

•failure of our information technology infrastructure or inability to protect against cyber-attack;

•our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;

•our ability to generate net cash flow from operations;

•our ability to service our debt and ability to raise funds necessary to settle conversions of the 2030 Notes or 2026 Notes in cash, repay the 2030 Notes or 2026 Notes at maturity, repurchase the 2030 Notes upon the exercise of the holders’ one-time put right or repurchase the 2030 Notes or the 2026 Notes in the case of a fundamental change;

•our ability to comply with the covenants contained in our 2030 Indenture, 2026 Indenture and other current or future debt agreements, including the limitations, restrictions and prohibitions such covenants may impose on the way we conduct our business, including certain financial covenants, prohibitions on incurring additional debt if certain covenants are not met and restrictions on our ability to make certain investments and restricted payments;

•our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;

•fluctuations in our gross profit margins, operating income or loss and/or net income or loss;

•our ability to efficiently conduct business outside the U.S.;

•our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;

•our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;

•product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;

Table of Content

•our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;

•our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;

•disruption in our management information systems for inventory management, distribution, and other key functions;

•compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;

•our ability to maintain our status as a responsible contractor under federal rules and regulations;

•changes in, or interpretation of, tax rules and regulations;

•our inability to use a Form S-3 Registration Statement; and

•the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2024 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.

Recent Developments and Updates Regarding Strategic Initiatives

2025 Restructuring Plan

In March 2025, the Company authorized the next phase of its multi-faceted cost savings and restructuring initiative (the “2025 Restructuring Plan”). The 2025 Restructuring Plan includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities. Additionally, in May 2025, in response to the uncertain macroeconomic environment, the Company announced an incremental cost reduction initiative focused on labor force reductions that is expected to deliver significant cost savings in the second half of the year.

The Company expects to incur approximately $8.5 million to $14.5 million in pre-tax restructuring and other related costs by the end of the second fiscal quarter of 2026. The charges under the 2025 Restructuring Plan are expected to be primarily cash charges.

Table of Content

Divestitures

On October 31, 2025, the Company completed the sale of the 3DXpert and Oqton businesses, subject to customary adjustments.

The Company determined that the associated assets and liabilities met the held for sale criteria during September 2025, with approval by the Company's Board of Directors and the signing of the purchase agreement. Accordingly, the Company classified $1.6 million of assets and $5.1 million of liabilities as held for sale in the Company’s Consolidated Balance Sheet as of September 30, 2025. No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been classified as a discontinued operation in the accompanying condensed consolidated financial statements, as the sale of 3DXpert and Oqton does not constitute a strategic shift that would have a major effect on the Company’s operations.

Goodwill

In the second quarter of 2025, based primarily on macroeconomic uncertainties, our updated strategic plans and restructuring initiatives and the decline in our stock price, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated a triggering event requiring an interim goodwill impairment assessment on our Healthcare reporting unit. As a result of the quantitative interim impairment test performed in the second quarter of 2025, we concluded that there was no impairment, as the estimated fair value of the Healthcare reporting unit exceeded the carrying value.

While there was no impairment found during our interim goodwill impairment test in the second quarter of 2025, changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairments tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.

Background

We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.

Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this MD&A, the price and mix effects relate to changes in revenue that are not able to be specifically attributed to changes in unit volume or changes in foreign exchange rates.

Table of Content

RESULTS OF OPERATIONS

Comparison of Results of Operations


	Three Months Ended						Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		Change		September 30, 2025		September 30, 2024		Change
Revenue	$	91,249	$	112,940	$	(21,691)	$	280,627	$	329,097	$	(48,470)
Cost of sales	61,818		71,227		(9,409)		182,357		199,364		(17,007)
Selling, general and administrative expenses ("SG&A")	34,716		57,974		(23,258)		118,624		166,772		(48,148)
Research and development expenses ("R&D")	16,025		20,764		(4,739)		53,069		66,260		(13,191)
Asset impairment charges	—		143,733		(143,733)		—		143,733		(143,733)
Loss from operations	$	(21,310)	$	(180,758)	$	159,448	$	(73,423)	$	(247,032)	$	173,609

Revenue

The following tables sets forth changes in our revenue for the three and nine months ended September 30, 2025.


(Dollars in thousands)	Products				Services				Total
Revenue - three months ended September 30, 2024	$	72,968			$	39,972			$	112,940
Change in revenue:
Volume	(21,689)		(29.7)	%	(1,761)		(4.4)	%	(23,450)		(20.8)	%
Price/mix	(85)		(0.1)	%	—		—	%	(85)		(0.1)	%
Foreign currency translation	1,117		1.5	%	727		1.8	%	1,844		1.6	%
Net change	(20,657)		(28.3)	%	(1,034)		(2.6)	%	(21,691)		(19.2)	%
Revenue - three months ended September 30, 2025	$	52,311			$	38,938			$	91,249


(Dollars in thousands)	Products				Services				Total
Revenue - nine months ended September 30, 2024	$	208,752			$	120,345			$	329,097
Change in revenue:
Volume	(45,201)		(21.7)	%	(1,496)		(1.2)	%	(46,697)		(14.2)	%
Price/mix	(4,258)		(2.0)	%	—		—	%	(4,258)		(1.3)	%
Foreign currency translation	1,542		0.7	%	943		0.8	%	2,485		0.8	%
Net change	(47,917)		(23.0)	%	(553)		(0.4)	%	(48,470)		(14.7)	%
Revenue - nine months ended September 30, 2025	$	160,835			$	119,792			$	280,627

For the three months ended September 30, 2025, revenue decreased $21.7 million, or 19.2%, compared to the three months ended September 30, 2024. The decrease in revenue was primarily due to a decline in product revenue of $20.7 million driven by lower materials volume to customers in the dental, service bureaus, and jewelry markets, unfavorable price/mix, and the impact of the Geomagic divestiture. Service revenue decreased $1.0 million due to the impact of decreased volumes because of the Geomagic divestiture. Excluding the impact of the Geomagic divestiture, service revenue increased due to increased volumes.

For the nine months ended September 30, 2025, revenue decreased $48.5 million, or 14.7%, compared to the nine months ended September 30, 2024. The decrease in revenue was primarily due to a decline in product revenue of $47.9 million driven by lower materials volume to customers in the dental, service bureaus, and jewelry markets, and the impact of the Geomagic divestiture. Service revenue decreased $0.6 million due to the impact of decreased volumes because of the Geomagic divestiture. Excluding the impact of the Geomagic divestiture, service revenue increased due to increased volumes although we saw decreased sales to a certain key customer in the dental market

Table of Content

Cost of sales and gross profit

For the three months ended September 30, 2025, cost of sales decreased to $61.8 million compared to $71.2 million for the three months ended September 30, 2024. Declines primarily related to lower sales volumes in printers and materials which were partially offset an increase in service volume.

For the three months ended September 30, 2025, gross profit decreased $12.3 million, or 29.4%, compared to the three months ended September 30, 2024. The decrease in gross profit was primarily due to a combination of lower sales volumes and the impact of the Geomagic divestiture. Gross profit margin decreased to 32.3% compared to 36.9% in the prior year period, primarily due to the Geomagic divestiture and lower sales volumes.

For the nine months ended September 30, 2025, cost of sales decreased to $182.4 million compared to $199.4 million for the nine months ended September 30, 2024. This decline was primarily attributable to a lower volume of printer and material sales.

For the nine months ended September 30, 2025, gross profit decreased $31.5 million, or 24.3%, compared to the nine months ended September 30, 2024. The decrease in gross profit was primarily due to a combination of lower sales volumes and the impact of the Geomagic divestiture. Gross profit margin decreased to 35.0% compared to 39.4% in the prior year period, primarily due to the Geomagic divestiture and lower sales volumes.

Selling, general and administrative expenses

For the three months ended September 30, 2025, selling, general and administrative expenses ("SG&A") decreased $23.3 million, or 40.1%, compared to the three months ended September 30, 2024. The year-over-year decline in SG&A was primarily due to:

•$7.6 million decrease in third-party service provider and consulting costs due to the increased cost to complete our fiscal 2023 audit during the three months ended September 30, 2024 and decreased legal fees;

•$7.5 million decrease in compensation and benefits expense primarily related to lower compensation expense due to the impact of our restructuring actions and lower stock-based compensation expense due to the timing of awards and lower annual incentive compensation; and

•$7.3 million decrease in amortization expense related to intangible assets due to lower intangible asset balances which were reduced by prior-year impairment charges; which were partially offset by

•$1.4 million increase due to costs associated with our restructuring actions which were primarily related to severance.

For the nine months ended September 30, 2025, SG&A decreased $48.1 million, or 28.9%, compared to the nine months ended September 30, 2024. The year-over-year decline in SG&A was primarily due to:

•$24.8 million decrease in compensation and benefits expense primarily related to lower compensation expense due to the impact of our restructuring actions and lower stock-based compensation expense due to the timing of awards;

•$16.5 million decrease in third-party service provider and consulting costs due to the increased cost to complete our fiscal 2023 audit during the nine months ended September 30, 2024; and decreased legal fees; and

•$10.1 million decrease in amortization expense related to intangible assets due to lower intangible asset balances which were reduced by prior-year impairment charges; which were partially offset by

•$4.7 million increase due to costs associated with our restructuring actions which were primarily related to severance.

Research and development expenses

For the three months ended September 30, 2025, research and development expenses ("R&D") decreased $4.7 million, or 22.8%, compared to the three months ended September 30, 2024. The year-over-year decline in R&D was primarily due to:

•$2.3 million decrease in compensation and benefits expense and other R&D expenses primarily due to improved operating efficiency and cost reductions realized from our restructuring activities.

For the nine months ended September 30, 2025, R&D decreased $13.2 million, or 19.9%, compared to the nine months ended September 30, 2024. The year-over-year decline in R&D was primarily due to:

Table of Content

•$9.1 million decrease in compensation and benefits expense and other R&D expenses primarily due to improved operating efficiency and cost reductions realized from our restructuring activities.

Segment Results


	Segment Revenue						Segment Gross Profit
	Three Months Ended						Three Months Ended
(in thousands)	September 30, 2025		September 30, 2024		Change		September 30, 2025		September 30, 2024		Change
Healthcare Solutions	$	42,787	$	55,056	$	(12,269)	$	16,420	$	23,322	$	(6,902)
Industrial Solutions	48,462		57,884		(9,422)		13,011		18,391		(5,380)
Total Company	$	91,249	$	112,940	$	(21,691)	$	29,431	$	41,713	$	(12,282)


	Segment Revenue						Segment Gross Profit
	Nine Months Ended						Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		Change		September 30, 2025		September 30, 2024		Change
Healthcare Solutions	$	129,123	$	149,369	$	(20,246)	$	52,826	$	62,739	$	(9,913)
Industrial Solutions	151,504		179,728		(28,224)		45,444		66,994		(21,550)
Total Company	$	280,627	$	329,097	$	(48,470)	$	98,270	$	129,733	$	(31,463)

Healthcare Solutions

Revenue

For the three months ended September 30, 2025, Healthcare Solutions revenue decreased $12.3 million, or 22.3%, compared to the three months ended September 30, 2024. The decrease in revenue was primarily due to a decline in materials revenue of $11.6 million. The decline in materials revenue was primarily due to lower sales in the dental market, including lower materials volume with a key customer.

For the nine months ended September 30, 2025, Healthcare Solutions revenue decreased $20.2 million, or 13.6%, compared to the nine months ended September 30, 2024. The decrease in revenue was primarily due to a decline in materials revenue of $25.3 million which was partially offset by an increase in service revenue of $4.5 million. The decline in materials revenue was primarily due to lower sales in the dental market, including lower materials volume with a key customer. Service revenue increased due to growth in parts manufacturing and personalized healthcare solutions revenue.

Gross profit

For the three months ended September 30, 2025, Healthcare Solutions gross profit decreased $6.9 million, or 29.6%, compared to the three months ended September 30, 2024. The decrease in gross profit was primarily due to lower sales volumes.

For the nine months ended September 30, 2025, Healthcare Solutions gross profit decreased $9.9 million, or 15.8%, compared to the nine months ended September 30, 2024. The decrease in gross profit was primarily due to lower sales volumes and unfavorable price/mix.

Industrial Solutions

Revenue

For the three months ended September 30, 2025, Industrial Solutions revenue decreased $9.4 million, or 16.3%, compared to the three months ended September 30, 2024. The decrease in revenue related to lower product, materials, and service revenue of $6.2 million, $1.9 million, and $1.3 million, respectively. The decline in product revenue was driven by the impact of the Geomagic divestiture and lower materials and printer sales to customers in the service bureaus and jewelry markets which was partially offset by increased sales in the aerospace and defense market. The decline in service revenue was primarily due to the impact of the Geomagic divestiture.

Table of Content

For the nine months ended September 30, 2025, Industrial Solutions revenue decreased $28.2 million, or 15.7%, compared to the nine months ended September 30, 2024. The decrease in revenue related to lower product, materials and service revenue of $15.7 million, $7.4 million, and $5.0 million, respectively. The decline in product revenue was driven by lower printer and materials sales to customers in the service bureaus and jewelry markets and the impact of the Geomagic divestiture which was partially offset by increased sales in the aerospace and defense market. The decline in service revenue was primarily due to the impact of the Geomagic divestiture.

Gross profit

For the three and nine months ended September 30, 2025, Industrial Solutions gross profit decreased $5.4 million, or 29.3%, and $21.6 million, or 32.2%, respectively, compared to the prior periods. The decrease in gross profit was primarily due to the impact of the Geomagic divestiture, unfavorable price and mix, and lower sales volumes.

Non-operating income (expense)

The following table sets forth the components of non-operating income:


	Three Months Ended						Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		Change		September 30, 2025		September 30, 2024		Change

Foreign exchange gain (loss), net	$	2,623	$	(1,960)	$	4,583	$	2,171	$	(774)	$	2,945
Interest income	784		1,550		(766)		3,454		5,800		(2,346)
Interest expense	(1,924)		(606)		(1,318)		(3,202)		(1,944)		(1,258)
Gain on disposition	—		—		—		125,681		—		125,681
Other income (loss), net	475		(51)		526		7,335		21,719		(14,384)
Total non-operating income (loss)	$	1,958	$	(1,067)	$	3,025	$	135,439	$	24,801	$	110,638

Foreign exchange gain, net

Foreign exchange gain, net increased by $4.6 million and $2.9 million for the three and nine months ended September 30, 2025, respectively, compared to the prior year periods, primarily due to realized and unrealized gains related to our foreign operations.

Interest income

Interest income decreased $0.8 million and $2.3 million for the three and nine months ended September 30, 2025, respectively, compared to the prior year periods, due to the Company's lower average cash and cash equivalent balances.

Interest expense

Interest expense increased by $1.3 million for both the three and nine months ended September 30, 2025, compared to the prior year periods, primarily due to interest expense related to the 2030 Notes.

Gain on disposition

The gain on disposition of $125.7 million for the nine months ended September 30, 2025 was due to the sale of Geomagic business on April 1, 2025.

Other income, net

Other income, net, increased $0.5 million for the three months September 30, 2025 as compared to the three months ended September 30, 2024, primarily due to a gain on the repurchase of debt in the three months ended September 30, 2025.

Other income, net, decreased $14.4 million for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024, primarily due to a higher gain on the repurchase of debt in the nine months ended September 30, 2024.

Income Taxes

For the three and nine months ended September 30, 2025, the Company’s effective tax rate was 13.6% and 14.6%, respectively. For the three and nine months ended September 30, 2024, the Company’s effective tax rate was 2.4% and 1.1%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three and nine months ended September 30, 2025 and 2024 were primarily driven by the recognition of a full deferred tax asset valuation allowance in various

Table of Content

jurisdictions in both years. Additionally, the nine months ended September 30, 2025, were impacted by a gain recognized in connection with the divestiture of Geomagic and some foreign return to provision adjustments recorded in the period.

Liquidity and Capital Resources

The following table sets forth the Company's operating working capital at September 30, 2025 and December 31, 2024.


	September 30, 2025		December 31, 2024		Change
(in thousands)					$		%
Cash and cash equivalents	$	95,542	$	171,324	$	(75,782)	(44.2)	%
Accounts receivable, net	88,074		101,471		(13,397)		(13.2)	%
Inventories	132,469		118,530		13,939		11.8	%
	316,085		391,325		(75,240)		(19.2)	%
Less:

Current operating lease liabilities	11,789		9,514		2,275		23.9	%
Accounts payable	39,182		41,833		(2,651)		(6.3)	%
Accrued and other liabilities	48,521		45,488		3,033		6.7	%
	99,492		96,835		2,657		2.7	%
Operating working capital	$	216,593	$	294,490	$	(77,897)	(26.5)	%

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments, acquisitions and divestitures.

At September 30, 2025, cash, cash equivalents and restricted cash totaled $114.2 million. Cash and cash equivalents totaled $95.5 million and decreased $75.8 million since December 31, 2024. This decrease resulted primarily from cash used in operations of $73.1 million, capital expenditures of $8.0 million, and cash used in financing activities of $98.3 million which was partially offset by proceeds from the sale of Geomagic of $119.4 million. Restricted cash totaled $18.7 million and is primarily related to the requirements of our 2030 Notes and reflected in other assets.

Cash held outside the U.S. at September 30, 2025 was $40.5 million, or 42.4% of total cash and cash equivalents, compared to $63.8 million, or 37.7% of total cash and cash equivalents, at December 31, 2024. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.

Table of Content

Cash Flow

The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. While challenging macroeconomic conditions, both in general and specific to the 3D printing industry, have had an impact on our financial performance and cash flows, we expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity, equity-linked, and/or debt securities, subject to market conditions, will be available and sufficient to meet our anticipated cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:


	Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		Change
Cash flow used in operating activities	$	(73,131)	$	(37,109)	$	(36,022)
Cash flow provided by (used in) investing activities	108,276		(13,152)		121,428
Cash flow used in financing activities	(98,340)		(90,747)		(7,593)

Operating Activities

Cash flows used in operating activities were $73.1 million during the nine months ended September 30, 2025, an increase of $36.0 million, as compared to the nine months ended September 30, 2024. The year-over-year change in operating cash flows was primarily attributable to the following factors:

•Year-over-year decrease of $49.6 million in operating cash flows from net earnings, net of non-cash items due to unfavorable business performance and restructuring actions.

•The aggregate changes in trade accounts receivable, inventory, and trade accounts payable used $2.0 million of cash during the nine months ended September 30, 2025 as compared to using $1.4 million during the prior year comparable period. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.

•The aggregate change in prepaid expenses, other assets, accrued expenses, and other liabilities used $21.5 million in the nine months ended September 30, 2025 as compared to using $7.1 million in the prior year comparable period. The year-over-year changes were driven by the timing of accruals and payments and tax-related amounts.

Investing Activities

Net cash provided by investing activities was $108.3 million during the nine months ended September 30, 2025, an increase of $121.4 million, as compared to the nine months ended September 30, 2024, driven primarily by proceeds from the sale of the Geomagic business.

Financing Activities

Net cash used in financing activities was $98.3 million during the nine months ended September 30, 2025, an increase of $7.6 million, as compared to the nine months ended September 30, 2024, driven primarily by net repayments of long-term debt of $81.4 million and stock repurchases of $15.0 million.

Material Cash Requirements

The Company's material cash requirements consist of the following contractual and other obligations:

Indebtedness

Convertible senior secured notes due 2030

Table of Content

Convertible senior notes due 2026

The 2026 Notes were issued pursuant to an indenture dated November 16, 2021 (the “2026 Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee (the “Trustee”), in an initial aggregate principal amount of $460.0 million. Although the 2026 Notes do not bear regular interest and their principal does not accrete, they have an annual effective interest rate of 0.594%, reflecting original issue discounts, commissions, and offering expenses. The 2026 Notes had an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture. The 2026 Notes are scheduled to mature on November 15, 2026, unless earlier redeemed, repurchased, or converted in accordance with their terms.

At September 30, 2025, we had $126.7 million of outstanding long-term debt, comprising $34.7 million of 2026 Notes and $92.0 million of 2030 Notes. Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or strategic opportunities, which could result in higher financing costs.

Purchase Commitments

We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to software licenses, printer assemblies, inventory and capital expenditures. As of September 30, 2025, such purchase commitments totaled $17.4 million, with approximately $9.0 million, expected to be due within the next twelve months.

Table of Content

Leases

The Company had operating and financing lease obligations (inclusive of interest) of $91.2 million at September 30, 2025, primarily related to real estate and equipment leases, of which, approximately $18.0 million in payments are expected over the next twelve months.

Sources of Funding to Satisfy Material Cash Requirements

The Company believes that it has the financial resources needed to meet its anticipated cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.

Other Contractual Commitments

Indemnification

In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Critical Accounting Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

Goodwill & other long-lived assets, including intangible assets

Long-lived assets, including intangible assets

We review long-lived assets (or asset groups), including intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset (or asset group) may not be recoverable. We assess the recoverability of the carrying value of assets (or asset groups) held for use based upon a review of undiscounted projected cash flows. Impairment losses, where identified, are measured as the excess of the carrying value of a long-lived asset (or asset group) over its estimated fair value, as determined using discounted projected cash flows. Our estimation of discounted projected cash flows requires us to make certain assumptions, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates.

Goodwill

Goodwill represents the amount by which the purchase price paid to consummate a business combination exceeds the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in the business combination. Goodwill is required to be assigned to a reporting unit for purposes of subsequent measurement and, as of September 30, 2025 and December 31, 2024, all of our reported goodwill was assigned to our Healthcare reporting unit.

We assess goodwill for impairment at least annually and, between annual impairment assessments, when circumstances indicate that there is a likelihood of greater than 50% that the carrying value of a reporting unit, inclusive of any assigned goodwill, exceeds the reporting unit’s fair value. On a forward-looking basis, such circumstances may include (1) a significant and sustained decrease in the trading price of our common stock that may suggest that the fair value of the Company and, accordingly, the fair value of our Healthcare reporting unit has declined, (2) a significant adverse change in the business climate for our Healthcare reporting unit, (3) a significant adverse change in the performance of our Healthcare reporting unit and/or (4) a decision to dispose of a significant portion of our Healthcare reporting unit.

Table of Content

When required to be performed, a quantitative goodwill impairment test compares the carrying value of a reporting unit to its fair value, and a goodwill impairment charge results when the reporting unit’s carrying value exceeds its fair value. The performance of a quantitative goodwill impairment test requires management to apply significant estimates and judgment – particularly to (1) estimate the fair value of the Company and each of our reporting units and (2) determine the carrying value of each of our reporting units, since we do not maintain separate balance sheets for our reporting units.

We estimate the fair value of our reporting units based primarily upon discounted cash flow projections for their underlying operations, which requires us to make significant assumptions regarding estimated cash flows, including long-term revenue and expense forecasts, profit margins, discount rates and terminal growth rates. We develop these assumptions based on the market risks unique to each reporting unit. In addition to the use of discounted cash flow projections, when appropriate, our estimates of the fair values of our reporting units include the results of applying the guideline company valuation method, which is a market approach. The application of the guideline company valuation method requires us to make judgments regarding (1) the appropriate set of comparable publicly traded guideline peer companies for which observable market multiples should be considered and (2) the appropriate multiple(s) to select from the range of multiples that may be observed for those guideline companies. We separately use reasonable and consistent allocation methodologies and approaches to allocate asset and liability balances to our reporting units when an account balance is not directly attributable to a specific reporting unit.

The remaining goodwill assigned to our Healthcare reporting unit could become subject to impairment upon any decrease in the estimated fair value of the Healthcare reporting unit or any increase in the estimated carrying value of the Healthcare reporting unit. Accordingly, over time, the key estimates, assumptions, and judgments that were used to estimate the fair value of our Healthcare reporting unit may change due to factors such as changes in market conditions and/or the actual performance of our Healthcare reporting unit. Similarly, over time, the carrying value of our Healthcare reporting unit could increase due to factors such as capital expenditures and/or the composition of the assets and liabilities of the Company and the underlying process and estimates required to allocate assets and liabilities that are not directly attributable to a specific reporting unit between/amongst our reporting units. Any unfavorable changes to the key estimates, assumptions, judgments or inputs utilized in our most recent quantitative goodwill impairment test – either on an individual basis or in the aggregate – could result in the recognition of impairment charges in the future.

There have been no material changes to our critical accounting estimates described in our 2024 Annual Report on Form 10-K.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

For a discussion of market risks at December 31, 2024, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2024 Annual Report on Form 10-K. During the nine months ended September 30, 2025, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2024.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of September 30, 2025, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Interim Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of September 30, 2025 due to the material weaknesses discussed in our 2024 Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described in our 2024 Annual Report on Form 10-K. Related to these efforts was the development of a remediation plan to specifically address processes and activities intended to rectify the issues identified as part of the material weaknesses. These plans include, but are not limited to, increased training, enhanced documentation associated with existing policies, and talent enhancements designed to specifically address the identified weaknesses. Aside from these activities, the results of which continue to be evaluated, there were no changes in the Company’s internal control over financial reporting during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Content

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

The information relating to legal proceedings set forth under the header “Litigation” in Note 12 to the condensed consolidated financial statements as of and for the three months ended September 30, 2025 included in this Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors

Information regarding risk factors appears in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward Looking Statements," in Part I - Item 2 of this Form 10-Q in "Risk Factors" in Part I - Item 1A of our 2024 Annual Report on Form 10-K and “Risk Factors” in Part II – Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. There were no material changes during the three months ended September 30, 2025 to the risk factors reported in our 2024 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuance of Unregistered Securities and Issuer Purchases of Equity Securities

Issuances of Unregistered Securities

None.

Issuer Purchases of Equity Securities

The following table sets forth information with respect to purchases of the Company’s common stock on a trade date basis made during the three months ended September 30, 2025:


	Total number of shares (or units) purchased (a)	Average price paid per share (or unit) (b)
July 1, 2025 - July 30, 2025	—	$	—
August 1, 2025 - August 31, 2025	3,105	2.05
September 1, 2025 - September 30, 2025	103,472	2.12
Total	106,577	$	2.12

a.Represents shares of common stock surrendered to us for payment of tax withholding obligations in connection with the vesting of restricted stock awards and units.

b.The average price paid reflects the average market value of shares withheld for tax purposes.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Director and Officer Trading Arrangements

During the fiscal quarter ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K) for the purchase or sale of the Company’s securities.

Table of Content

Item 6. Exhibits


(a)			Exhibits
			The following exhibits are included as part of this filing and incorporated herein by this reference:
3.1			Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-B filed on August 16, 1993, and the amendment thereto, filed on Form 8-B/A on February 4, 1994.)
3.2			Amendment to Certificate of Incorporation filed on May 23, 1995. (Incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-2/A, filed on May 25, 1995.)
3.3			Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 19, 2004. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004, filed on August 5, 2004.)
3.4			Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 17, 2005. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2005, filed on August 1, 2005.)
3.5			Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on October 7, 2011. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on October 7, 2011.)
3.6			Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on May 21, 2013. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on May 22, 2013.)
3.7			Amended and Restated By-Laws. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on March 15, 2018.)
4.1			Specimen Common Stock Certificate. (Incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-3 (Registration No. 333-182065), filed on June 12, 2012.)
4.2			Indenture, dated as of November 16, 2021, between 3D Systems Corporation and The Bank of New York Mellon Trust Company, N.A., as trustee. (Incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed on November 17, 2021.)
4.3			Form of 0% Convertible Notes due 2026 (included in Exhibit 4.2). (Incorporated by reference to Exhibit 4.2 of the Registrant’s Current Report on Form 8-K filed on November 17, 2021.)
4.4			Indenture, dated June 23, 2025, among 3D Systems Corporation, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent. (Incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed on June 24, 2025.)
4.5			Form of 5.875% Convertible Senior Note due 2030 (included in Exhibit 4.4). (Incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed on June 24, 2025.)
31.1†			Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2†			Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1†			Certification of Principal Executive Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2†			Certification of Principal Financial Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS†			Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because the its XBRL tags are embedded within the Inline XBRL document
101.SCH†			Inline XBRL Taxonomy Extension Scheme Document
101.CAL†			Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF†			Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB†			Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE†			XBRL Taxonomy Extension Presentation Linkbase Document
104			Cover Page Interactive Data File - this data file does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document

† Exhibits filed herein. All exhibits not so designated are incorporated by reference to a prior filing, as indicated.

Table of Content

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	3D SYSTEMS CORPORATION:

Date: November 4, 2025	By	/s/ Phyllis Nordstrom
		Phyllis Nordstrom
		Interim Chief Financial Officer and Chief Administrative Officer

3D SYSTEMS CORP 10-Q